A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference
Study after study has demonstrated that these drugs decrease the overall chance of death, primarily by reducing the risk of cardiovascular events like heart attack or stroke, along with managing blood sugar and reducing obesity
Product Facts Supplement Facts Serving Size 1 Vegan Tablet Servings Per Container 100 *Daily Value not established
The caution is primarily about MTC and MEN2 risk, not about everyday hypothyroidism or even most other thyroid cancers
Chan AO, Leung G, Tong T, Wong NY
As of 2025, Retatrutide is in Phase 3 clinical trials